according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 9 to 12 in San Francisco. Akimasa Fukushi, MD, of Shionogi & Co., Ltd ...

Spotlight reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections. Several new ...

GSK's ViiV Healthcare released data at the Conference on Retroviruses and Opportunistic Infections showing the long-term efficacy of Apretude (cabotegravir long-acting) and Cabenuva (cabotegravir + ...

who presented the findings at the Conference on Retroviruses and Opportunistic Infections in San Francisco. “I was just so excited [to hear the results],” says Carina Marquez, an associate ...

today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic ...

SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed ...

These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Results from the EMBRACE study at the six-month primary endpoint showed: 96% of ...

Tecovirimat is Safe but Not Efficacious in People with Clade II Mpox Today’s presentation, which was highlighted in a CROI press conference, found that tecovirimat did not reduce the time to ...

The company used the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco to share data on three parts of its plan. Wednesday, ViiV published phase 2b data on its ...

Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. "This study brought us a step forward in better understanding mpox ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI ...

These findings, presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S., support the continued development of these two compounds as distinct ...